Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma-Reference-Cited by-同舟云学术

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

Published:2014-02-04 Issue:9 Volume:55 Page:2151-5160
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Herting Frank,Friess Thomas,Bader Sabine,Muth Gunter,Hölzlwimmer Gabriele,Rieder Natascha,Umana Pablo,Klein Christian

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.856008

Reference18 articles.

1. A unique cell surface antigen identifying lymphoid malignancies of B cell origin.

2. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

3. Rituximab for the Treatment of Non-Hodgkinʼs Lymphoma and Chronic Lymphocytic Leukaemia

4. Anti-CD20 Antibody Therapy for B-Cell Lymphomas

5. Treatment of follicular lymphoma: current status

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NNV024, a novel humanized anti-CD37 antibody with enhanced ADCC and prolonged plasma half-life in human FcRn transgenic mice for treatment of NHL;2023-07-12

2. Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study);Hematological Oncology;2022-06-05

3. Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with ⁹⁰Y or ¹⁷⁷Lu;Journal of Medicinal Chemistry;2022-04-20

4. Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors;International Journal of Hematology;2022-03-18

5. Genetic glycoengineering in mammalian cells;Journal of Biological Chemistry;2021-01